Nuvalent, Inc. NUVL Zidesamtinib — Direct Expenses Related To Program
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nuvalent, Inc. in its filing.
Tagged under the XBRL concept nuvl:DirectExpensesRelatedToProgram.
The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvalent, Inc.'s zidesamtinib — direct expenses related to program.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvalent, Inc.'s zidesamtinib — direct expenses related to program?
- Nuvalent, Inc. (NUVL) reported zidesamtinib — direct expenses related to program of $12.31M in Q1 2026.
- How has Nuvalent, Inc.'s zidesamtinib — direct expenses related to program changed year-over-year?
- Nuvalent, Inc.'s zidesamtinib — direct expenses related to program decreased by 20.8% year-over-year, from $15.55M to $12.31M.
- What is the long-term trend for Nuvalent, Inc.'s zidesamtinib — direct expenses related to program?
- Over 2 years (2023 to 2025), Nuvalent, Inc.'s zidesamtinib — direct expenses related to program has grown at a 46.1% compound annual growth rate (CAGR), from $27.88M to $59.52M.
- What does zidesamtinib — direct expenses related to program mean?
- The total direct costs incurred to develop and test a specific drug candidate.
- How do you interpret zidesamtinib — direct expenses related to program?
- An increase typically reflects accelerated clinical trial activity or expanded development scope, while a decrease may indicate program completion, cost-saving measures, or a shift in strategic priority.
- How does zidesamtinib — direct expenses related to program compare across companies?
- Comparable to R&D spend per clinical program at other early-stage biopharmaceutical companies, though it varies significantly based on the phase of clinical trials and the complexity of the therapeutic target.